ReviewDiscover oncology2025
Targeting TP53TG1: a promising prognostic biomarker and therapeutic target for personalized cancer therapy.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Insight into the emerging role of long non-coding RNAs in BRAF inhibitor resistance in melanoma.Frontiers in oncology · 2026Review
- Role of autophagy‑modulating long non‑coding RNAs in tumor radioresistance (Review).Oncology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor protein p53 target gene 1 (TP53TG1) is a significant long non-coding RNA (lncRNA) located on human chromosome 7q21.12, exhibiting dysregulated expression in several cancer tissues, and operates both as an oncogene and a tumor suppressor. TP53TG1 modulates gene expression by several mechanisms, including "competitive RNA" activity, competitive miRNA binding, control of critical signaling pathways, and facilitation of epigenetic changes. TP53TG1 affects tumor proliferation, migration, invasion, and apoptosis through intricate mechanisms, modifies tumor cells resistance to therapies, influences the tumor immune microenvironment and metabolic reprogramming, and may present various avenues for clinical therapeutic intervention. Notwithstanding considerable advancements in comprehending the molecular function of TP53TG1, some challenges persist, especially regarding the efficient and targeted administration of TP53TG1-based therapeutics. Advanced RNA delivery technologies, including lipid nanoparticles (LNPs), sphingomyelin-based nanosystems, and polymer-based nanocarriers, have demonstrated the capacity to surmount these obstacles. This review aims to clarify the expression pattern of TP53TG1 in 10 malignant tumors, its biological relevance, its potential as a therapeutic target, and its importance in clinical applications, thereby offering a novel perspective on molecular targeting in cancer. In the future, integrating TP53TG1 with conventional medications may augment efficacy, offer personalized treatments, and eventually increase the prognosis for patients with aggressive or drug-resistant cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.